Drug intelligence / Profile preview

Bifidobacterium infantis-TK

Development stage: Preclinical
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Gene Therapies
Administration: Intravenous, Intraperitoneal

Overview

Bifidobacterium infantis-TK is a gene therapy construct that utilizes the anaerobic bacterium Bifidobacterium infantis as a delivery vehicle for the herpes simplex virus thymidine kinase (HSV-TK) gene. This system is designed for suicide gene therapy, where the HSV-TK enzyme converts a prodrug, such as ganciclovir, into a cytotoxic metabolite, leading to the death of cells expressing the enzyme. It has been investigated for its antitumor effects, specifically in models of renal cell carcinoma.

Targets

HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))

Beyond the preview

Go deeper on Bifidobacterium infantis-TK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium infantis-TK.

Explore the full profile